Many aspects of Lactobacillus reuteri and its functions in the body have been mapped out, but there is still a great deal to be explored.

Scientifically based claims

Strong network of independent researchers

BioGaia collaborates with specialists at more than 50 research institutions and clinics that study Lactobacillus reuteri at both a preclinical and clinical level.

BioGaia’s research network is unique in several respects. Firstly because many of the researchers are global leaders in their fields, and secondly because some of the collaborations have been underway since BioGaia was founded 27 years ago. The company also has a significant breadth that extends across many different indications on both the pediatric and adult side. Furthermore, the aim is not only to establish that Lactobacillus reuteri works, but also how and why. For that ­reason, there is also preclinical research, i.e. research conducted in a laboratory with the help of different models.
    The objective is for all research to conform to the highest possible scientific standards. Regular publication of data on Lactobacillus reuteri in ­medical journals is a testimony to strong scientific relevance and high research quality.

Research already in the 80s

Already before BiogGaia was founded, intensive research on Lactobacillus reuteri was being conducted at places such as the Swedish University of Agricultural Sciences (SLU) in Uppsala. There, Sven Lindgren and Walter Dobrogosz studied how Lactobacillus reuteri was able to inhibit pathogenic microorganisms such as E. coli and Salmonella. Stefan Roos then moved on to pre­clinical research by determining how Lactobacillus reuteri binds to the intestinal mucous membrane. Stefan defended his thesis on this in 1999 and he still works part time as a researcher at SLU, but for the past three years he has also been employed by BioGaia, where he is responsible for coordinating preclinical research.

Preclinical research gives us valuable knowledge

“Over the years, many aspects of Lactobacillus reuteri and its functions in the body have been mapped out, although numerous questions still remain to be answered,” says Stefan. “For instance, we know that Lactobacillus reuteri in preclinical models has a beneficial effect on gut motility, reduces perceived pain intensity and can prevent the intestinal mucous membrane from leaking bacteria and toxic substances. These so-called mechanisms of action most likely lie behind the clinical effects shown by Lactobacillus reuteri.
    “In other words, preclinical research gives us knowledge about how the probiotic bacteria work, which is important for several reasons. First and foremost, this knowledge can generate ideas for how to develop more effective products, but it also adds to the credibility of the products,” says Stefan.

BioGaia year